ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.38
0.74%
US Tech 100
20,836.00
1.31%
S&P 500
5,930.85
1.09%
US Dollar vs CAD
1.43421
0.00%
Bitcoin
96,255.19
-0.98%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. NovoCure Ltd (NVCR) Share Price

NovoCure Ltd

NovoCure Ltd (NVCR)

NASDAQ
30.80
0.40
(1.32%)
Closed December 22 3:00PM
Delayed by 15 minutes
30.8005
0.0005
(0.00%)
After Hours: 6:59PM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
30.80
Bid
30.50
Ask
84.37
Volume
1,693,696
30.46 Day's Range 31.52
11.70 52 Week Range 34.13
Market Cap
3.333B
Previous Close
30.40
Open
30.465
Last Trade
10
@
30.99
Last Trade Time
Financial Volume
US$ 52,567,754
VWAP
31.0373
Average Volume (3m)
1,348,273
Shares Outstanding
108,201,434
Dividend Yield
-
PE Ratio
-16.11
Earnings Per Share (EPS)
-1.91
Revenue
509.34M
Net Profit
-207.04M

About NovoCure Ltd

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives it... NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Website
www.novocure.com
Headquarters
Jersey, Gbr
Founded
-
NovoCure Ltd is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker NVCR. The last closing price for NovoCure was US$30.40. Over the last year, NovoCure shares have traded in a share price range of US$ 11.70 to US$ 34.13.

NovoCure currently has 108,201,434 shares outstanding. The market capitalization of NovoCure is US$3.29 billion. NovoCure has a price to earnings ratio (PE ratio) of -16.11.

Ask ADVFN Intelligence (AI)

NVCR Latest News

More News

Novocure annonce des résultats positifs de l'essai clinique de phase 3 PANOVA-3 sur les champs de traitement des tumeurs (TTFields) pour le cancer du pancréas

PANOVA-3 a atteint son objectif principal avec une amélioration statistiquement importante de la survie globale des patients atteints d'un adénocarcinome pancréatique non résécable et localement...

December 05 2024
Business Wire

ノボキュア、膵がんに対する腫瘍治療電場療法（TTフィールド）の第3相臨床試験PANOVA-3のトップライン結果を発表

PANOVA-3試験でゲムシタビンおよびnab-パクリタキセルと併用したTTフィールドを一次治療として用いた切除不能な局所進行膵腺がん患者の全生存期間が統計的に有意に改善、主要評価項目を達成 アメリカ、EU、日本...

December 04 2024
Business Wire

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

PANOVA-3 met its primary endpoint with a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma treated in the...

December 02 2024
Business Wire

Form 8-K - Current report

December 02 2024
Edgar (US Regulatory)

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

PANOVA-3 met its primary endpoint with a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma treated in the first...

December 02 2024
Business Wire

Novocure to Participate in Upcoming Investor Conferences

Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences: Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024, in Coral Gables...

November 27 2024
Business Wire

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual Scientific Meeting and Education Day of...

November 21 2024
Business Wire

FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its...

November 21 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

November 06 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.050.16260162601630.7534.1329.79140811331.91125459CS
413.6179.173938336217.1934.1317.16192650228.83293627CS
1214.7992.379762648316.0134.1314.17134827322.28694961CS
2611.660.416666666719.234.1314.17132390320.11071264CS
5217.27127.64227642313.5334.1311.7132937418.09382564CS
156-53.01-63.250208805683.81120.0310.87109603538.33953569CS
260-54.55-63.913298183985.35232.7610.87100974967.17234781CS

NVCR - Frequently Asked Questions (FAQ)

What is the current NovoCure share price?
The current share price of NovoCure is US$ 30.80
How many NovoCure shares are in issue?
NovoCure has 108,201,434 shares in issue
What is the market cap of NovoCure?
The market capitalisation of NovoCure is USD 3.29B
What is the 1 year trading range for NovoCure share price?
NovoCure has traded in the range of US$ 11.70 to US$ 34.13 during the past year
What is the PE ratio of NovoCure?
The price to earnings ratio of NovoCure is -16.11
What is the cash to sales ratio of NovoCure?
The cash to sales ratio of NovoCure is 6.55
What is the reporting currency for NovoCure?
NovoCure reports financial results in USD
What is the latest annual turnover for NovoCure?
The latest annual turnover of NovoCure is USD 509.34M
What is the latest annual profit for NovoCure?
The latest annual profit of NovoCure is USD -207.04M
What is the registered address of NovoCure?
The registered address for NovoCure is NO 4 THE FORUM, GRENVILLE STREET, ST. HELIER, JERSEY, JE2 4UF
What is the NovoCure website address?
The website address for NovoCure is www.novocure.com
Which industry sector does NovoCure operate in?
NovoCure operates in the SURGICAL,MED INSTR,APPARATUS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MYSZMy Size Inc
US$ 4.2001
(211.12%)
121.03M
NVNINVNI Group Ltd
US$ 8.26
(209.36%)
78.06M
TPICTPI Composites Inc
US$ 2.45
(100.82%)
34M
ICGIntchains Group Ltd
US$ 8.77
(88.60%)
527.94k
HSDTHelius Medical Technologies Inc
US$ 0.884851
(84.34%)
121.95M
CYNCYNGN Inc
US$ 0.4603
(-71.41%)
27.91M
MTEMMolecular Templates Inc
US$ 0.1502
(-57.09%)
8.75M
PRFXPainReform Ltd
US$ 5.15
(-53.85%)
2.94M
GALTGalectin Therapeutics Inc
US$ 1.03
(-48.50%)
9.27M
BCABBioAtla Inc
US$ 0.6923
(-41.82%)
6.25M
EDBLEdible Garden AG Inc
US$ 0.24
(65.06%)
354.33M
NVDANVIDIA Corporation
US$ 134.70
(3.08%)
310.19M
APTOAptose Biosciences Inc
US$ 0.28
(64.51%)
306.25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.606999
(6.49%)
293.22M
PLTRPalantir Technologies Inc
US$ 80.55
(8.54%)
281.23M

NVCR Discussion

View Posts
whosleftholdindabag whosleftholdindabag 1 week ago
$NVCR has reached its 52-week high! Wishing everyone a great weekend! GLTA
👍️0
PonkenPlonken PonkenPlonken 3 weeks ago
Thank you for sharing!
They seem to believe this makes it to market in CRC is my read.
👍️0
jondoeuk jondoeuk 3 weeks ago
A phase 2 trial, PANOVA-4, will test TTFields combined with a triplet regimen of gemcitabine, nab-paclitaxel and atezolizumab as a first-line treatment for metastatic pancreatic ductal adenocarcinoma. It has completed enrolment and the company said it expects to have data in 2026.

The primary endpoint is disease control rate (DCR). Secondary endpoints include, overall survival (OS), progression-free survival (PFS), 1-year OS rate, objective response rate (ORR), PFS at 6 months, duration of response, and safety.
👍️0
whosleftholdindabag whosleftholdindabag 3 weeks ago
$NVCR what a great way to kick off December, don't you know? Where are all the bloody naysayers today? We're raising a lot of money for charity! GLTA
👍️0
jondoeuk jondoeuk 3 weeks ago
Novocure plans to file for regulatory approval in the U.S., EU, Japan and other key markets; Zai Lab plans to file for regulatory approval in China https://www.businesswire.com/news/home/20241202363277/en/Zai-Lab-and-Novocure-Announce-Positive-Topline-Results-from-Phase-3-PANOVA-3-Clinical-Trial-of-Tumor-Treating-Fields-TTFields-Therapy-for-Pancreatic-Cancer
👍️ 1
tw0122 tw0122 3 weeks ago
Looking good $30 +
50% 
12:09 PM EST, 12/02/2024 (MT Newswires) -- (Updates with stock move in the headline and first paragraph.)NovoCure's (NVCR) shares rose more than 41% in recent Monday trading after the company and Zai Lab (ZLAB) said that their phase 3 trial evaluating TTFields along with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma achieved its primary endpoint, demonstrating a "statistically significant" improvement in median overall survival.NovoCure (NVCR) plans regulatory filings in the US, EU, Japan, and other major markets, while Zai Lab plans to file for regulatory approval in China, the companies said.
👍️0
PonkenPlonken PonkenPlonken 3 weeks ago
would love to see new session high
data is hot --- Can become SOC
👍️0
whosleftholdindabag whosleftholdindabag 3 weeks ago
$NVCR back above $20! GLTA
👍️0
Invest-in-America Invest-in-America 2 months ago
NVCR: One has to be patently BRAIN DEAD to attribute any significance whatsoever to the 1890's-like ELECTRICAL, cure-all, gadgets that this obvious SCAM company promotes!!!
👍️ 1
jondoeuk jondoeuk 2 months ago
FDA Approves Novocure’s Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer https://www.businesswire.com/news/home/20241015381082/en
👍️ 1 💥 1
whosleftholdindabag whosleftholdindabag 2 months ago
Lovely action AH $NVCR! I can't wait for the opening bell, wishing everyone a great evening! GLTA
👍️0
whosleftholdindabag whosleftholdindabag 2 months ago
$NVCR great way to end the trading day! GLTA
👍️0
whosleftholdindabag whosleftholdindabag 2 months ago
I own both $NVCR and $NWBO, all proceeds will go to charity. GLTA
👍️0
KIPK KIPK 2 months ago
Glad to see you are in the right stock, NWBO, now!!
👍️0
TiltMyBrain TiltMyBrain 4 months ago
Who is the bag holder now???

Going to single digits
👍️ 1
whosleftholdindabag whosleftholdindabag 5 months ago
Come fly with me, let's fly let's fly away! Ol blue eyes, what a beautiful voice! Great start $NVCR! GLTA
🚽 2
whosleftholdindabag whosleftholdindabag 5 months ago
Back above $20 $NVCR! GLTA
🚽 1
whosleftholdindabag whosleftholdindabag 7 months ago
Another week, another beautiful day for $NVCR shareholders! GLTA
🐀 1
whosleftholdindabag whosleftholdindabag 7 months ago
Another beautiful start of the week for $NVCR! GLTA
😂 1
KIPK KIPK 7 months ago
LOL - Go from over $200 to $20.
Wondering why this charity worker is NWBO hater.
Wondering why a self proclaimed good spirit tries so hard to destroy a great cancer therapy company. NWBO, hat is not NVCR??
A true charity worker expected to be compassionate, caring, and greatful of all possible potentials...

BUT not this guy??

You judge!!!

KARMA!!
👍️ 3 💯 2
whosleftholdindabag whosleftholdindabag 7 months ago
GO $NVCR GO! We're making A LOT of $$$$$ for charities don't you know? GLTA
⚠️ 1
whosleftholdindabag whosleftholdindabag 7 months ago
Beautiful day $NVCR! GLTA
👎️ 2 🤣 2
whosleftholdindabag whosleftholdindabag 7 months ago
It's been another great week for $NVCR! Have a wonderful weekend everyone! GLTA
👎️ 2 🚫 1 🤣 1
TiltMyBrain TiltMyBrain 7 months ago
Insiders to sell shares in 30 days
👍️ 2 💥 2
KIPK KIPK 8 months ago
LOL 🤣🤣🤣
👍️ 2 💯 1
dstock07734 dstock07734 8 months ago
Or you can simply wait.
👍️ 1 🤣 2
whosleftholdindabag whosleftholdindabag 8 months ago
Well that's fantastic mate! Perhaps I'll have my lawyer contact her, have a great weekend! GLTA
🤣 1 ⚠️ 1
dstock07734 dstock07734 8 months ago
By now, you should be smart enough to know that Laura Posner or Elliott Leary would be able to get IP address of each poster on NWBO board.
👍️ 4
dstock07734 dstock07734 8 months ago
libel? Which part is libel? Nemesis18's post style is very similar to yours, would you agree?
👍️ 3 🤣 2
whosleftholdindabag whosleftholdindabag 8 months ago
No, do you? GLTA
⚠️ 1
whosleftholdindabag whosleftholdindabag 8 months ago
I'd be careful you're getting a wee bit close to libel don't you know? GLTA
🚫 1 🤣 1
whosleftholdindabag whosleftholdindabag 8 months ago
Great way to end the week! Finish strong $NVCR! Have a great weekend everyone! GLTA
🚫 1 🤣 1
whosleftholdindabag whosleftholdindabag 8 months ago
You're posting on the wrong board mate, $NWBO is the one dealing with toxic financers go over there and post your rubbish! GLTA

Streeterville Capital, LLC is a Chicago-based company owned by John M. Fife, who has been described as a "toxic lender" for many years. Toxic financing is a type of financing that companies use when they are in poor condition and can't get financing in any other way. It can come in the form of convertible debt or convertible preferred stock and often gives the debtholder an unlimited number of common shares when they convert their debt or preferred shares to common stock.
👍️ 1
TiltMyBrain TiltMyBrain 8 months ago
Toxic financing for a company who’s price is down 90% in last 3 years
👍️ 2 💥 2
TiltMyBrain TiltMyBrain 8 months ago
Today is the pump. Tomorrow is the insider dump
👍️ 2 💥 2
KIPK KIPK 8 months ago
What a great day right Nemeses 18?
How is dat charity holding da bag???
👍️ 2 😂 2 🤣 1
KIPK KIPK 8 months ago
Gone with the wind on wings of fake therapy IMO
👍️ 2 💯 1
KIPK KIPK 9 months ago
20? including a PRE-CLINICAL???? lol
And all that unfocused activity signal the total desperation to keep the SP up IMO...

Reminds me of INO, which also kept throwing stuff at every possible thing, hoping one would stick.... But NO... INO SP at one time was over $2000 & now is around $11 after a recent RS
👍️ 1
axelvento axelvento 9 months ago
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

https://www.biospace.com/article/releases/novocure-announces-20-presentations-on-tumor-treating-fields-highlighting-preclinical-effects-in-pancreatic-cancer-and-immune-effects-at-american-association-for-cancer-research-aacr-annual-meeting-2024/
👎️ 2 🤣 1
TiltMyBrain TiltMyBrain 9 months ago
https://x.com/peter_brit/status/1775041789889491437?s=46&t=1nHn7IXseo2gJ7ymtRCgUA

This ship is sinking fast!
👍️ 3 👏 3
TiltMyBrain TiltMyBrain 9 months ago
insider selling in 3...2...1...
👍️ 3 💯 3 😂 1 🤣 1
TiltMyBrain TiltMyBrain 9 months ago
"Preliminary analyses of key secondary endpoints (time to neurocognitive failure, overall survival, and radiological response rate) did not demonstrate statistical significance."

pump and dump in progress
👍️ 2 💯 2 🤣 1
whosleftholdindabag whosleftholdindabag 9 months ago
Loving the early action on $NVCR. Wishing everybody a great day! GLTA
🐀 1 🗑️ 1 🤣 2
KIPK KIPK 9 months ago
LOL - "In time to Intracranial Progression" ??? SMH
👍️ 1
Awl416 Awl416 9 months ago
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
👍️ 2 💯 1
KIPK KIPK 9 months ago
The Vanishing tin can on the wind of ineffectiveness!!
Have a kick at it MATE - LOL !!
👍️ 1
KIPK KIPK 9 months ago
You just made a positive post for NWBO without knowing it MATE. Think JAMA.....

And that's So sad as You must be in total loss for words to be citing here a post by a Paid NWBO Basher, InquiriNg. At least you should have given the credit as she, just like you, has been lost for words as well MATE!! . LOL Mate!!

You Birt got nothing & the tin hat is made for a tin man... just like you & the charity investor scamwannabe!!
LOL
👍️ 4 🤣 2
jondoeuk jondoeuk 9 months ago
NWBO's DCVax-L is an expensive placebo. The same is true for DCVax-Direct.
👍️ 1 💯 1 🗑️ 3 ❌️ 2
KIPK KIPK 9 months ago
Congrats whosbagholding. You keep expanding your reach into Charity Work. LOL - SMH...

Below is a response to one of your good will intention (LOL) on NWBO MB>>>>
Re: AAPL31415926 post# 679357

Monday, March 18, 2024 8:40:02 AM

Post#
679360
of 679363
Amazing that whosbagholding gave me a clown emoji on this comment. It shows how absolutely evil these people are. Hopefully he/she/it/they don't have to face their spouse or one of their children being diagnosed with a fatal disease that they work hard to try and destroy a cure for. Then again there's always karma.
👍️0
KIPK KIPK 10 months ago
Who S Left Hold In D Bag - LOL LOL LOL LOL - Brit Mate?? LOL
👍️ 2 🤣 2

Your Recent History

NASDAQ
NVCR
NovoCure
AMEX
XUSP
Innovator Uncapped Accel...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads